Sandeep Gurram,Nityam Rathi
Sandeep Gurram
Intravesical therapy is a critical component in the management of non-muscle-invasive bladder cancer (NMIBC), as it reduces rates of disease recurrence and progression. However, the presence of physiologic barriers in the urothelium reduces...
Mark S Soloway,Neil A Abrahams
Mark S Soloway
Piyush K Agarwal,Cora N Sternberg
Piyush K Agarwal
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy [0.03%]
多中心分析淋巴结密度和分期对膀胱癌根治术患者特异性生存的影响
Erik J van Gennep,Francesco Claps,Peter J Bostrom et al.
Erik J van Gennep et al.
Background: Prognostic tools in pathological-node (pN) patients after radical cystectomy (RC) are needed. Objectives: To evaluate the p...
Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer [0.03%]
肌层浸润性膀胱癌治疗中的患者决策因素分析
Avani Desai,Lucas Bouknight,Thomas Reed et al.
Avani Desai et al.
Background: In 2023, an estimated 82,290 individuals were diagnosed with bladder cancer in the United States. For muscle-invasive bladder cancer (MIBC), the American Urological Association recommends offering radical cyst...
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It [0.03%]
非肌层浸润性膀胱癌：许多患者是死于该病而非因该病去世
Kathryn McGonagle,Ellen J Dematt,Zhibao Mi et al.
Kathryn McGonagle et al.
Background: The National Cancer Institute SEER Program regularly publishes bladder-cancer specific survival statistics. However, this data is for all bladder cancers, and information for non-muscle invasive bladder cancer...
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis [0.03%]
新辅助顺铂、吉西他滨和多西他赛治疗梭形细胞膀胱癌：临床活性及全转录组分析
Burles A Johnson Iii,Benjamin A Teply,Catherine Kagemann et al.
Burles A Johnson Iii et al.
Background: Sarcomatoid urothelial cancer of the bladder (SBC) is a rare, but aggressive histological subtype for which novel treatments are needed. Objec...
Edward M Messing
Edward M Messing
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward [0.03%]
那多法拉基因非达诺韦克的发展历程：综述与展望路径
Alexis R Steinmetz,Sharada Mokkapati,David McConkey et al.
Alexis R Steinmetz et al.
Background: The intravesical gene therapy nadofaragene firadenovec (rAd-IFNα/Syn3) was FDA approved in 2022 for non-muscle invasive bladder cancer (NMIBC) unresponsive to frontline treatment with BCG, and the first gene ...
Incidental Prostate Cancer in Radical Cystoprostatectomy Specimens is Associated with Worse Overall Survival [0.03%]
根治性膀胱前列腺切除标本中的意外发现前列腺癌与总体生存率降低有关
Takahiro Kimura,Hajime Onuma,Shun Sato et al.
Takahiro Kimura et al.
Background: The impact of incidental prostate cancer (IPC) on oncological outcomes after radical cystoprostatectomy (RCP) specimens from patients with bladder cancer (BC) remains controversial. This relationship has not b...